Analysis of the CDK4/6 Cell Cycle Pathway in Leiomyosarcomas as a Potential Target for Inhibition by Palbociclib

Figure 3

(a) Expression of p16 pathway proteins and Ki-67 index of leiomyosarcoma tissue and assumed increased probability to potential response of palbociclib treatment. Multiple samples from the same patient are marked by their matching sample number (e.g., 6.1 and 6.2); uterine tumours are marked with . S.-Nr., sample number; PRT, potential responder phenotype; P, primary tumour; M, metastasis; R, recurrence; and P, primary tumour after neoadjuvant chemotherapy. (b) Exemplary H.E. staining and immunohistochemistry. Negative staining for p16, strong expression of CDK4, CDK6, and p-Rb. Bars: 100 µm and 200 µm for H.E.